Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NP137,Atezolizumab,Bevacizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Netris Pharma Doses First Patient in Hepatocellular Carcinoma (HCC) Clinical Study with NP137
Details : NP137 is a humanized monoclonal antibody of isotype IgG1 directed against netrin-1. Most types of tumors produce an abnormal amount of dependence receptors’ ligands, which prevents cells from apoptosis.
Product Name : NP137
Product Type : Antibody
Upfront Cash : Inapplicable
January 26, 2023
Lead Product(s) : NP137,Atezolizumab,Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NETRIS Pharma Doses First Patient in Phase 2 Study of NP137 for Checkpoint Inhibitor Resistance
Details : NP137 is a humanized monoclonal antibody of isotype IgG1 directed against netrin-1. Most types of tumors produce an abnormal amount of dependence receptors’ ligands, which prevents cells from apoptosis.
Product Name : NP137
Product Type : Antibody
Upfront Cash : Inapplicable
November 29, 2022
Details : Preclinical studies show NP137 to have an anti-cancer effect as a monotherapy as well as synergistic effects in combination with chemotherapy or immune checkpoint inhibitors.
Product Name : NP137
Product Type : Antibody
Upfront Cash : Undisclosed
September 20, 2022
Reset All
